Welcome, Guest. Please login or register.
November 08, 2024, 07:46:18 pm

Login with username, password and session length


Members
Stats
  • Total Posts: 55133
  • Total Topics: 4851
  • Online Today: 254
  • Online Ever: 3061
  • (September 25, 2024, 11:40:40 pm)
Users Online
Users: 0
Guests: 231
Total: 231

Welcome

Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: FDA OKs Cocrystal Pharma’s Study of a 2- to 4-Week Hep C Treatment  (Read 5498 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
The Food and Drug Administration (FDA) has approved the investigational new drug application from Cocrystal Pharma for its experimental hepatitis C virus (HCV) drug CC-31244, clearing the way for a Phase IIa trial of the medication.

CC-31244 is a broad-spectrum nonnucleoside inhibitor that in earlier trials demontrated a high barrier to resistance, meaning hep C is unlikely to develop mutations associated with resistance to the drug during treatment. The medication is also active against all six genotypes of hep C and has shown a low level of toxicity in multiple types of cells.

Read more...
https://www.hepmag.com/article/fda-oks-cocrystal-pharmas-study-2-4week-hep-c-treatment

 


© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.